



Hyperbaric Oxygen Therapy in the Treatment of COVID-19 Patients

Hyperbaric Oxygen Therapy (HBOT), involves breathing 100% Oxygen in a pressurized chamber. The treatment is cleared by the FDA; however, treating respiratory distress in COVID-19 positive patients is not an approved indication. Initial studies show COVID-19 triggers an intense immune response leading to pulmonary inflammation and hypoxia. HBOT has the potential to increase oxygen delivery, alleviate symptoms and reduce inflammation. Ongoing research aims to determine if HBOT can help COVID-19 patients recover more rapidly and decrease the need for mechanical ventilation.

SerenaGroup® is working with its hospital partners to evaluate the safety and efficacy of the compassionate use of HBOT to reduce the need for mechanical ventilation in COVID-19 patients. SerenaGroup® has developed IRB-approved protocols, and policies and procedures to safeguard patients and clinicians.

Hyperbaric Oxygen and COVID-19: Clinical trials registered on clinicaltrials.gov

[https://www.uhms.org/images/Position-Statements/HBO2 and COVID v2 clinical trials on clinicaltrials.gov.pdf](https://www.uhms.org/images/Position-Statements/HBO2%20and%20COVID%20v2%20clinical%20trials%20on%20clinicaltrials.gov.pdf)

For more information contact Dr. Thomas Serena
serena@serenagroups.com or C. 814-688-4000

www.serenagroupinc.com

25
YEARS
1995-2020


AAWC

Association for
the Advancement
of Wound Care®

On April 29, 2020 – Dr. Serena and other professional colleagues partnered with AAWC & presented a case study webinar on **HBOT for the treatment of COVID-19**.

To view the webinar including 5 case studies, go to the AAWC website to view – or use the link below.

<https://aawconline.memberclicks.net/2020-hbot-for-the-treatment-of-covid-19>



**COVID-19: Clinical/Therapeutic
Staging Proposal and Treatment**